Introducing Our Lead Product, YuuthTM – Repairing Cellular Imbalance to Restore Youthful Beauty
Ponce Therapeutics is using advanced technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs, both senolytic and senomorphic in nature, utilize novel therapeutics discovered using our proprietary, state-of-the-art biotechnology platforms to restore the youthful balance of aged or “senescent” and young cells systemically and directly in the skin. This leads to a resetting of one’s biologic clock, turning back time on one’s body and skin to its former youthful exuberance.
Proprietary Platform
Targeting Senescent Cells for Secretory Modification or Elimination
Elimination of senescent cells or reduction of their pro-inflammatory secretory phenotype has been shown to suppress cancer and rejuvenate tissues.
Clinical Pipeline
Development of our lead programs targeting senescent cells in skin and throughout the body
PONCE’s lead programs, both senolytic and senomorphic, aim to restore a more youthful cellular balance throughout the body.
Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin
Ponce Therapeutic's ("Ponce") lead product, ReBeaut™, is a microneedle patch containing nanoparticles carrying its proprietary ApoptiCIDe™ cell elimination gene therapy technology targeting senescent keratinocytes and fibroblasts in the skin Speratum Biopharma ("Speratum")…
Read More